Eli Lilly LLY
Eli Lilly is a U.S. pharmaceutical company that develops and commercializes innovative medicines, with a primary focus on diabetes, obesity, and oncology. Eli Lilly shows exceptional fundamentals with a 102% ROE, 83% gross margin, and 48% revenue growth, but its valuation is demanding (P/E 39.7) and regulatory pricing pressure is a risk to watch.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Eli Lilly is a U.S. pharmaceutical company that develops and commercializes innovative medicines, with a primary focus on diabetes, obesity, and oncology. Eli Lilly shows exceptional fundamentals with a 102% ROE, 83% gross margin, and 48% revenue growth, but its valuation is demanding (P/E 39.7) and regulatory pricing pressure is a risk to watch.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.1 |
| Quality / Moat | 8.7 |
| Valuation | 2.9 |
| Growth | 9.0 |
| Dividend | 4.4 |
| Momentum | 9.1 |
| Risk & Context | 7.9 |
OVERALL SCORE: 6.5/10
Context and risks
Regulatory pressure on drug prices in the US (Inflation Reduction Act) is a known sector risk. Lilly's exposure to Medicare price setting for key drugs like Mounjaro and Zepbound is a concrete risk that could impact its future growth.
News considered in the analysis
- Eli Lilly Just Announced Game-Changing News — El titular sugiere un anuncio potencialmente transformador, pero al ser vago y de una fuente especulativa, el impacto se modera y se descuenta parcialmente.
- Eli Lilly and Company (LLY) is Expanding Beyond Its Biggest Growth Drivers. Can it Sustain the Momentum? — La expansión más allá de los motores de crecimiento actuales (diabetes y obesidad) es una señal positiva, pero la pregunta sobre la sostenibilidad del impulso introduce incertidumbre.
- Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch — Artículo de agenda que menciona a Lilly entre otras, sin información específica sobre la empresa.
- Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades? — Noticia sobre un competidor directo, sin impacto directo en los fundamentales de Lilly.
- Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? — Comparativa genérica entre otras dos empresas del sector salud, sin información relevante para Lilly.
Verdict: Hold positions; the strength of the business justifies the premium, but regulatory risk and valuation limit near-term upside.
Main risk: The main risk is US regulatory pressure on drug pricing, which could directly impact revenue from its top-selling drugs (Mounjaro, Zepbound).
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →